Sphera Funds Management’s BioAtla BCAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-3,732
Closed -$1.54M 85
2022
Q4
$1.54M Buy
+3,732
New +$1.55M 0.33% 46
2022
Q1
Sell
-3,600
Closed -$3.53M 73
2021
Q4
$3.53M Sell
3,600
-686
-16% -$877K 0.39% 63
2021
Q3
$6.31M Buy
+4,286
New +$8.35M 0.53% 58
2021
Q1
Sell
-1,000
Closed -$1.7M 176
2020
Q4
$1.7M Buy
+1,000
New +$1.67M 0.15% 91

Other funds holding BCAB

Sphera Funds Management's BCAB Position: Q1 2023 in Review

Sphera Funds Management sold out of BioAtla (BCAB) in Q1 2023, closing a stake of 3,732 shares — an estimated $1.54M sold.

Sphera Funds Management first reported a position in BCAB in Q4 2020 and held it in 4 quarters. The position peaked at $6.31M in Q3 2021. 79 funds tracked by Wall St. Rank hold BCAB as of Q1 2023.

  • Sphera Funds Management reported no remaining BioAtla position as of Q1 2023 after selling out during the quarter.
  • Sphera Funds Management sold 3,732 BioAtla shares in Q1 2023, an estimated $1.54M.
  • Sphera Funds Management first reported a position in BioAtla in Q4 2020 and held it in 4 quarters.
  • Sphera Funds Management's BioAtla position peaked at $6.31M in Q3 2021.
  • 79 funds tracked by Wall St. Rank held BioAtla as of Q1 2023.

Based on Sphera Funds Management's 13F filing for Q1 2023, filed 15 May 2023.